source
- Tiziana's intranasal MS drug shows lower dose cuts neuroinflammation, higher dose falls short in Phase 2a trialTiziana Life Sciences reported results from its mid‑stage Inform‑MS trial, a Phase 2a study that enrolled 48 patients with non‑active secondary progressive multiple sclerosis. Participants received…
- Midterm voters weigh health-care costs as urgent-care visits billed like ERsThe upcoming midterm elections will see tens of millions of voters consider health‑care affordability, especially those whose coverage comes through their employers. The article points out that ri…